SCHEMBL561772

SCHEMBL561772

FC(F)(F)c1cc(Cl)nc(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
CYP3A4 P08684 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
HIF1A Q16665 1/20 0.40
TXNRD1 Q16881 1/20 0.40
TXNRD3 Q86VQ6 1/20 0.40
TXNRD2 Q9NNW7 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
GABRA2 P47869 5/20 0.38
GABRB2 P47870 5/20 0.38
NFKB1 P19838 4/20 0.38
NFKB2 Q00653 4/20 0.38
RELA Q04206 4/20 0.38
JUN P05412 3/20 0.38
XPO1 O14980 1/20 0.38
CES2 O00748 1/20 0.37
GABRB3 P28472 7/20 0.36
GABRP O00591 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL28186521 0.87 CES2 (0.39) ALDH1A1CYP3A4HPGDALOX15TSHR
SCHEMBL4703323 0.85 ADORA2A (0.39) ALDH1A1CYP3A4HPGDALOX15TSHR
SCHEMBL12788231 0.85 TACR1 (0.37) ALDH1A1CYP3A4HPGDALOX15TSHR
SCHEMBL11109288 0.84 S1PR1 (0.36) ALDH1A1CYP3A4HPGDALOX15TSHR
SCHEMBL29560454 0.84 NOS3 (0.45) ALDH1A1CYP3A4HPGDALOX15TSHR
SCHEMBL23181498 0.84 GABRB3 (0.36) ALDH1A1CYP3A4HPGDALOX15TSHR
SCHEMBL562878 0.84 HSP90AA1 (0.39) GABRA2GABRB2GABRB3NPC1RAB9A
SCHEMBL29256257 0.84 XPO1 (0.36) ALDH1A1CYP3A4HPGDALOX15TSHR
SCHEMBL29659055 0.84 HSP90AA1 (0.39) GABRA2GABRB2GABRB3NPC1RAB9A
SCHEMBL2087532 0.84 NOS3 (0.45) ALDH1A1CYP3A4HPGDALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 492 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114790168-B Preparation method of 2-amino-4-trifluoromethyl pyridine and 2-amino-4-trifluoromethyl pyridine 上海素馨化工科技有限公司 2024-02-09 CN claimed
CN-111151248-A Method for catalyzing heterocyclic halogen-containing organic matter hydrogenation dehalogenation by using supported metal oxide 浙江大学 2020-05-15 CN claimed
US-4563529-A VAPOR PHASE CATALYTIC FLUORINATION OF PICOLINES OR LUTIDINES ISHIHARA SANGYO KAISHA LTD. (JP) 1986-01-07 US claimed
EP-0042696-B1 PROCESS FOR PRODUCING TRIFLUOROMETHYLPYRIDINES ISHIHARA SANGYO KAISHA LTD. (JP) 1983-11-16 EP claimed
EP-0042696-A1 Process for producing trifluoromethylpyridines ISHIHARA SANGYO KAISHA LTD. (JP) 1981-12-30 EP claimed
JP-4005273-A None JP disclosed
US-12630528-B2 Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof LG CHEM, LTD. (KR) 2026-05-19 US disclosed
US-12630534-B2 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds as GPR139 antagonists for the treatment of e.g. depression TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2026-05-19 US disclosed
US-12590086-B2 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2026-03-31 US disclosed
EP-4695259-A1 TRICYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS F. Hoffmann-La Roche AG (CH) 2026-02-18 EP disclosed
US-20260035367-A1 PKC-Theta Modulators CELGENE CORPORATION (US) 2026-02-05 US disclosed
US-20260022130-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2026-01-22 US disclosed
US-4649201-A SOLVENT EXTRACTION, ALKYLENE GLYCOL THE DOW CHEMICAL COMPANY (US) 1987-03-10 US disclosed
US-4563529-A VAPOR PHASE CATALYTIC FLUORINATION OF PICOLINES OR LUTIDINES ISHIHARA SANGYO KAISHA LTD. (JP) 1986-01-07 US disclosed
EP-0042696-B1 PROCESS FOR PRODUCING TRIFLUOROMETHYLPYRIDINES ISHIHARA SANGYO KAISHA LTD. (JP) 1983-11-16 EP disclosed
EP-0042696-A1 Process for producing trifluoromethylpyridines ISHIHARA SANGYO KAISHA LTD. (JP) 1981-12-30 EP disclosed
EP-0004434-B1 HALOMETHYL SUBSTITUTED DIALKOXYPYRIDINES, FUNGICIDAL COMPOSITION, AND METHOD FOR PROTECTING PLANTS FROM FUNGAL DISEASE THE DOW CHEMICAL COMPANY (US) 1981-09-30 EP disclosed
US-4203988-A ANTISECRETORY AGENTS MERCK & CO., INC. (US) 1980-05-20 US disclosed
US-4190662-A FUNGICIDES THE DOW CHEMICAL COMPANY (US) 1980-02-26 US disclosed
EP-0004434-A2 Halomethyl substituted dialkoxypyridines, fungicidal composition, and method for protecting plants from fungal disease THE DOW CHEMICAL COMPANY (US) 1979-10-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022130-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS LIPC, LIPA, LPL ALDH1A1 1338/4885CYP3A4 784/4885HPGD 2377/4885
US-20260035367-A1 PKC-Theta Modulators PRKAR2B, PRKAR2A, PRKCD ALDH1A1 4459/4885CYP3A4 2376/4885HPGD 3114/4885
US-12590086-B2 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression GPR139, OPRL1, GRIN2C ALDH1A1 1460/4885CYP3A4 1767/4885HPGD 3996/4885
US-12630528-B2 Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof DGAT2, DGAT1, SOAT2 ALDH1A1 597/4885CYP3A4 1556/4885HPGD 2277/4885
US-12630534-B2 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds as GPR139 antagonists for the treatment of e.g. depression GPR139, OPRL1, GRIN2C ALDH1A1 1685/4885CYP3A4 2449/4885HPGD 4155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.